phosphodiesterase inhibitor

(redirected from PDE4 inhibitor)

phosphodiesterase inhibitor

Abbreviation: PDE inhibitor
Any agent that blocks phosphodiesterase, inhibiting the production of second messengers within cells, such as cyclic adenosine monophosphate or cyclic glucose monophosphate. Drugs that inhibit PDE include sildenafil, an agent used to treat erectile dysfunction, and other agents used as positive inotropes and vasodilators in heart failure.
See also: inhibitor
References in periodicals archive ?
"Targeted Delivery of an Anti-Inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-Drug Conjugate." Molecular Therapy 24, no.
for rights to develop and commercialize vTv Therapeutics' PDE4 Inhibitor program in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries covering Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei and South Korea.
Apremilast, a PDE4 inhibitor, is an oral agent approved for psoriasis.
Medimetriks has exclusive US rights to develop and commercialize MM36, a non-steroidal topical anti-inflammatory PDE4 inhibitor that is believed to exert anti-inflammatory action by inhibiting the production of cytokines and chemical mediators thought to cause the signs and symptoms of AD.
In recent years, studies of another PDE4 inhibitor, CHF6001, have reached similar conclusions [130].
Capone et al., "Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity," Cellular Signalling, vol.
Anacor's flagship asset, crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, is currently under review by the US FDA for the treatment of mild-to-moderate atopic dermatitis, commonly referred to as eczema.
Anacors flagship asset, crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, is presently being reviewed by the U.S.
Materials and Methods: To investigate whether PDE4B regulates additional inflammatory mediators other than TNF-a, in this study we initially used two-dimensional gel electrophoresis approach to screen the secreted proteins that are modulated by the PDE4 inhibitor rolipram in LPS-stimulated Raw 264.7 macrophages.
Upon completion of the transaction, AstraZeneca will own the development and commercial rights to Tudorza Pressair (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD), and Daliresp (roflumilast), a once-daily oral PDE4 inhibitor currently on the market for COPD.
Additionally, AstraZeneca will own the development and commercial rights in the US and Canada Daliresp (roflumilast), the only once-daily oral PDE4 inhibitor currently on the market for COPD.
We next observed that MPs released from PMVECs pretreated with 10 [micro]M isoproterenol (a [beta]-adrenergic agonist) and 10 [micro]M rolipram (a PDE4 inhibitor) had markedly elevated cAMP levels (Bauer and Sayner, data not shown).